The challenge and promise of anti-epileptic therapy development in animal models

The Lancet Neurology

Volumn 13, Issue 9, 2014, Pages 949-960

  Simonato, Michele ^a   Brooks Kayal, Amy R ^b   Engel, Jerome ^c   Galanopoulou, Aristea S ^d   Jensen, Frances E ^e   Moshé, Solomon L ^d   O'Brien, Terence J ^f   Pitkanen, Asla ^g,h   Wilcox, Karen S ⁱ   French, Jacqueline A ^j  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITY OF EASTERN FINLAND   (Finland)

^h KUOPIO UNIVERSITY HOSPITAL   (Finland)

ⁱ UNIVERSITY OF UTAH   (United States)

^j NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; BIOLOGICAL MARKER; ETIRACETAM; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEUROTRANSMITTER; TOPIRAMATE;

ANIMAL MODEL; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMORBIDITY; EPILEPSY; EPILEPTOGENESIS; HIGH RISK PATIENT; HUMAN; METABOLISM; NEUROLOGIC DISEASE; NONHUMAN; NOTE; PRIORITY JOURNAL; SEIZURE; TRAUMATIC BRAIN INJURY; VALIDATION STUDY; ANIMAL; DISEASE MODEL; DRUG SCREENING; STANDARDS; DRUG EFFICACY; ECONOMICS; EXPERIMENTAL ANIMAL; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PUBLICATION; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EPILEPSY; HUMANS;

EID: 84906280998     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70076-6     Document Type: Note

References (49)

1. Löscher W, Schmidt D Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011, 52:657-678.
2. Galanopoulou AS, Buckmaster PS, Staley KJ, et al. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 2012, 53:571-582. the American Epilepsy Society Basic Science Committee, The International League Against Epilepsy Working Group On Recommendations For Preclinical Epilepsy Drug DiscoveryThe International League Against Epilepsy Working Group On Recommendations For Preclinical Epilepsy Drug Discovery.
3. Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009, 40:2244-2250. the STAIR Group.
4. Shineman DW, Basi GS, Bizon JL, et al. Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther 2011, 3:28.
5. Steward O, Popovich PG, Dietrich WD, Kleitman N Replication and reproducibility in spinal cord injury research. Exp Neurol 2012, 233:597-605.
6. Ludolph AC, Bendotti C, Blaugrund E, et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler 2010, 11:38-45.
7. Brooks-Kayal AR, Bath KG, Berg AT, et al. Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy. Epilepsia 2013, 54(suppl 4):44-60.
8. Galanopoulou AS, Kokaia M, Loeb JA, et al. Epilepsy therapy development: technical and methodologic issues in studies with animal models. Epilepsia 2013, 54(suppl 4):13-23.
9. Hooijmans CR, Leenaars M, Ritskes-Hoitinga M A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible. Altern Lab Anim 2010, 38:167-182.
10. Kahle MP, Bix GJ Successfully Climbing the "STAIRs": Surmounting Failed Translation of Experimental Ischemic Stroke Treatments. Stroke Res Treat 2012, 2012:374098.
11. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010, 8:e1000412.
12. Landis SC, Amara SG, Asadullah K, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012, 490:187-191.
13. Making methods clearer. Nat Neurosci 2013, 16:1. Editorial.
14. Improving the Quality of NINDS-Supported Preclinical and Clinical Research through Rigorous Study Design and Transparent Reporting Rigor in Science Working Group. http://www.ninds.nih.gov/funding/transparency_in_reporting_guidance.pdf.
15. Simonato M, Löscher W, Cole AJ, et al. Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia 2012, 53:1860-1867.
16. Simonato M, French JA, Galanopoulou AS, O'Brien TJ Issues for new antiepilepsy drug development. Curr Opin Neurol 2013, 26:195-200.
17. Löscher W, Klitgaard H, Twyman RE, Schmidt D New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov 2013, 12:757-776.
18. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005, 46:470-472.
19. Fisher RS, Acevedo C, Arzimanoglou A, et al. A practical clinical definition of epilepsy. Epilepsia 2014, 55:475-482.
20. Pitkänen A, Nehlig A, Brooks-Kayal AR, et al. Issues related to development of antiepileptogenic therapies. Epilepsia 2013, 54(suppl 4):35-43.
21. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:1069-1077.
22. Wilcox KS, Dixon-Salazar T, Sills GJ, et al. Issues related to development of new antiseizure treatments. Epilepsia 2013, 54(suppl 4):24-34.
23. Engel J, Pitkänen A, Loeb JA, et al. Epilepsy biomarkers. Epilepsia 2013, 54(suppl 4):61-69.
24. Katz R Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004, 1:189-195.
25. National Institute of Neurological Disorders and Stroke (accessed Aug 4, 2014). http://www.ninds.nih.gov/research/asp/asp_working_group_report_022712.htm.
26. French JA, White HS, Klitgaard H, et al. Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia 2013, 54(suppl 4):3-12.
27. Zeng LH, Xu L, Gutmann DH, Wong M Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008, 63:444-453.
28. Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013, 74:679-687.
29. Rakhade SN, Jensen FE Epileptogenesis in the immature brain: emerging mechanisms. Nat Rev Neurol 2009, 5:380-391.
30. Meador KJ, French J, Loring DW, Pennell PB Disparities in NIH funding for epilepsy research. Neurology 2011, 77:1305-1307.
31. Pitkänen A, Lukasiuk K Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 2011, 10:173-186.
32. Blumenfeld H, Klein JP, Schridde U, et al. Early treatment suppresses the development of spike-wave epilepsy in a rat model. Epilepsia 2008, 49:400-409.
33. Dezsi G, Ozturk E, Stanic D, et al. Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy. Epilepsia 2013, 54:635-643.
34. Cook MJ, O'Brien TJ, Berkovic SF, et al. Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study. Lancet Neurol 2013, 12:563-571.
35. Fisher RS, Blum DE, DiVentura B, et al. Seizure diaries for clinical research and practice: limitations and future prospects. Epilepsy Behav 2012, 24:304-310.
36. Engel J Biomarkers in epilepsy: introduction. Biomarkers Med 2011, 5:537-544.
37. Engel J, da Silva FL High-frequency oscillations - where we are and where we need to go. Prog Neurobiol 2012, 98:316-318.
38. Worrell G, Gotman J High-frequency oscillations and other electrophysiological biomarkers of epilepsy: clinical studies. Biomarkers Med 2011, 5:557-566.
39. Gomes WA, Shinnar S Prospects for imaging-related biomarkers of human epileptogenesis: a critical review. Biomarkers Med 2011, 5:599-606.
40. 11C]-methyl-L-tryptophan PET for tracer localization of epileptogenic brain regions: clinical studies. Biomarkers Med 2011, 5:577-584.
41. Pitkänen A, Lukasiuk K Molecular biomarkers of epileptogenesis. Biomarkers Med 2011, 5:629-633.
42. Vezzani A, Friedman A Brain inflammation as a biomarker in epilepsy. Biomarkers Med 2011, 5:607-614.
43. O'Brien TJ, Ben-Menachem E, Bertram EH, et al. Proposal for a "phase II" multicenter trial model for preclinical new antiepilepsy therapy development. Epilepsia 2013, 54(suppl 4):70-74.
44. Mullard A Reliability of 'new drug target' claims called into question. Nat Rev Drug Discov 2011, 10:643-644.
45. Prinz F, Schlange T, Asadullah K Believe it or not: how much can we rely on published data on potential drug targets?. Nat Rev Drug Discov 2011, 10:712.
46. Kimmelman J, Anderson JA Should preclinical studies be registered?. Nat Biotechnol 2012, 30:488-489.
47. Button KS, Ioannidis JP, Mokrysz C, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 2013, 14:365-376.
48. Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012, 78:1548-1554.
49. Baillie TA, Rettie AE Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism. Drug Metab Pharmacokinet 2011, 26:15-29.